Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer

BACKGROUND: The trastuzumab, pertuzumab, and docetaxel (TPD) regimen is strongly recommended as a treatment option for first-line therapy for advanced human epidermal growth factor receptor (HER) 2-positive breast cancer. Monitoring the host microenvironments in cancer plays a significant role in pr...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Transl Med
Asıl Yazarlar: Takada, Koji, Kashiwagi, Shinichiro, Goto, Wataru, Asano, Yuka, Takahashi, Katsuyuki, Takashima, Tsutomu, Tomita, Shuhei, Ohsawa, Masahiko, Hirakawa, Kosei, Ohira, Masaichi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2018
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5883877/
https://ncbi.nlm.nih.gov/pubmed/29615076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-018-1460-4
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller